Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation

por Osterman, Mark T., Rosario, Maria, Lasch, Karen, Barocas, Morris, Wilbur, Jayson D., Dirks, Nathanael L., Gastonguay, Marc R.
Publicado 2019

Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis

por Sandborn, William J, Colombel, Jean-Frédéric, Panaccione, Remo, Dulai, Parambir S, Rosario, Maria, Cao, Charlie, Barocas, Morris, Lasch, Karen
Publicado 2019

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

por Narula, Neeraj, Peerani, Farhad, Meserve, Joseph, Kochhar, Gursimran, Chaudrey, Khadija, Hartke, Justin, Chilukuri, Prianka, Koliani-Pace, Jenna, Winters, Adam, Katta, Leah, Shmidt, Eugenia, Hirten, Robert, Faleck, David, Parikh, Malav P., Whitehead, Diana, Boland, Brigid S., Singh, Siddharth, Sagi, Sashidhar Varma, Fischer, Monika, Chang, Shannon, Barocas, Morris, Luo, Michelle, Lasch, Karen, Bohm, Matthew, Lukin, Dana, Sultan, Keith, Swaminath, Arun, Hudesman, David, Gupta, Nitin, Shen, Bo, Kane, Sunanda, Loftus, Edward V., Siegel, Corey A., Sands, Bruce E., Colombel, Jean-Frederic, Sandborn, William J., Dulai, Parambir S.
Publicado 2019